Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Perfluoropropane human albumin microspheres is an injectable ultrasound contrast agent consisting of perfluoropropane gas encapsulated within human serum albumin microspheres. It is designed to enhance the backscatter of ultrasound waves, thereby improving the visualization of cardiac structures during echocardiography. The microspheres are small enough to pass through the pulmonary capillary bed, allowing for opacification of the left ventricular chamber and improved delineation of the endocardial borders. This agent is particularly useful in patients where standard echocardiography yields suboptimal images. Xiamen LiZhuo Pharmaceutical has received approval for this agent in China for use in cardiac ultrasound contrast, marking it as a significant domestic generic alternative to established global brands like Optison.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on perflutren protein-type A microspheres.